ArticleVaccine2017
Immunization of Zika virus envelope protein domain III induces specific and neutralizing immune responses against Zika virus.
Article in Vaccine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 111 citations in OpenAlex.
- Multivalent display of envelope protein domain III with Mi3 nanoparticles induces protective immunity against lethal Zika virus infection in mice.Virologica Sinica · 2026Article
- Discovery and computational characterization of ZIKV envelope-targeted peptides from a subtractive phage display library.PloS one · 2026Article
- Rapid virus-free production of recombinant yellow fever virus envelope protein and its in-depth biophysical analysis.Scientific reports · 2025Article
- Deep Mutational Scanning in Immunology: Techniques and Applications.Pathogens (Basel, Switzerland) · 2025Review
- Induction of systemic and mucosal immune response against Zika virus by vaccination with non-infectious chimeric VLPs.Scientific reports · 2025Article
- A VLPs based vaccine protects against Zika virus infection and prevents cerebral and testicular damage.NPJ vaccines · 2025Article
- A Lambda-evo (λApplied microbiology and biotechnology · 2025Article
- Comparison of Three Chimeric Zika Vaccine Prototypes Developed on the Genetic Background of the Clinically Proven Live-Attenuated Japanese Encephalitis Vaccine SAInternational journal of molecular sciences · 2024Article
- An Overview of Zika Virus and Zika Virus Induced Neuropathies.International journal of molecular sciences · 2024Review
- Characterization of a plant-derived monoclonal antibody targeting extracellular enveloped virions of Monkeypox virus.Frontiers in plant science · 2024Article
- EDIII-Fc induces protective immune responses against the Zika virus in mice and rhesus macaque.PLoS neglected tropical diseases · 2023Article
- Production of Recombinant Zika Virus Envelope Protein by Airlift Bioreactor as a New Subunit Vaccine Platform.International journal of molecular sciences · 2023Article
- A Dual-Approach Strategy to Optimize the Safety and Efficacy of Anti-Zika Virus Monoclonal Antibody Therapeutics.Viruses · 2023Article
- Antibody-Dependent Enhancement Activity of a Plant-Made Vaccine against West Nile Virus.Vaccines · 2023Article
- Diagnostic and vaccine potential of Zika virus envelope protein (E) derivates produced in bacterial and insect cells.Frontiers in immunology · 2023Article
- Vaccination with a Zika virus envelope domain III protein induces neutralizing antibodies and partial protection against Asian genotype in immunocompetent mice.Tropical medicine and health · 2022Article
- ZIKV-envelope proteins induce specific humoral and cellular immunity in distinct mice strains.Scientific reports · 2022Article
- Zika Virus Envelope Protein Domain III Produced inDiagnostics (Basel, Switzerland) · 2022Article
- Article
- In silico construction of a multiepitope Zika virus vaccine using immunoinformatics tools.Scientific reports · 2022Article
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
In this study, we described the generation and immunogenicity of the Zika Virus (ZIKV) envelope protein (E) domain III (DIII) as a protein subunit vaccine candidate. ZIKV EDIII (zEDIII) was rapidly produced in E. coli in inclusion bodies. ZIKV EDIII was solubilized, refolded and purified to >95% homogeneity with a one-step Ni
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.